Tyra Biosciences, Inc. (TYRA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -160.46M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 126.32M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-160.46M | (m) | (m) | $126.32M | (m) | (m) |
| 2026-03-31 | $-142.91M | (m) | (m) | $111.43M | (m) | (m) |
| 2025-12-31 | $-132.76M | (m) | (m) | $102.93M | (m) | (m) |
| 2025-09-30 | $-125.99M | (m) | (m) | $96.92M | (m) | (m) |
| 2025-06-30 | $-121.63M | (m) | (m) | $94.15M | (m) | (m) |
| 2025-03-31 | $-113.70M | (m) | (m) | $87.84M | (m) | (m) |
| 2024-12-31 | $-104.18M | (m) | (m) | $80.08M | (m) | (m) |
| 2024-09-30 | $-100.07M | (m) | (m) | $78.57M | (m) | (m) |
| 2024-06-30 | $-95.45M | (m) | (m) | $75.15M | (m) | (m) |
| 2024-03-31 | $-87.93M | (m) | (m) | $69.31M | (m) | (m) |
| 2023-12-31 | $-79.94M | (m) | (m) | $62.52M | (m) | (m) |
| 2023-09-30 | $-69.33M | (m) | (m) | $52.24M | (m) | (m) |
| 2023-06-30 | $-59.01M | (m) | (m) | $43.89M | (m) | (m) |
| 2023-03-31 | $-58.43M | (m) | (m) | $43.77M | (m) | (m) |
| 2022-12-31 | $-58.93M | (m) | (m) | $43.01M | (m) | (m) |
| 2022-09-30 | $-53.84M | (m) | (m) | $39.86M | (m) | (m) |
| 2022-06-30 | $-46.83M | (m) | (m) | $34.43M | (m) | (m) |
| 2022-03-31 | $-36.91M | (m) | (m) | $26.76M | (m) | (m) |
| 2021-12-31 | $-26.29M | (m) | (m) | $20.64M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-9.30M | (m) | (m) | $7.20M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |